| Bioactivity | BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of<0.001 μM[1]. |
| Target | IC50: <0.001 μM (BTK) |
| Invitro | BTK-IN-19 (Compound 51) (3 days) inhibits B-cell proliferation with an IC50 of 0.080 μM[1].BTK-IN-19 (Compound 51) (3 days) 抑制 B 细胞增殖，IC50 为 0.080 μM[1]。 Cell Proliferation Assay[1] Cell Line: |
| In Vivo | BTK-IN-19 (Compound 51) (80 mg/kg; i.p.; once) 在小鼠中抑制 CD69[1]。BTK-IN-19 (5 mg/kg; p.o.) 在大鼠中体内清除率低，具有适中的口服利用度 (%F > 34) [1]。 Animal Model: |
| Name | BTK-IN-19 |
| CAS | 1374240-01-3 |
| Formula | C21H22Cl2N6O |
| Molar Mass | 445.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vandeveer GH, et al. Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. Bioorg Med Chem Lett. 2022 Dec 17;80:129108. |